GlassScriptPhysician profile
Sreeram Maddipatla
NPI 1891946646
$25,351.25
in general payments reported to CMS, 2019-2025
15 companies · $3,795 in 2025
The $3,795 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $4,065 · 2021: $31.49 · 2022: $3,568 · 2023: $3,544 · 2024: $158 · 2025: $3,795.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,660 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,000 · Travel and Lodging: $1,249 · Food and Beverage: $588.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,660.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,000.00 |
| Travel and Lodging | $1,248.81 |
| Food and Beverage | $587.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $10,040.83 | 2019-2023 | Reblozyl |
| Acceleron Pharma, INC. | $4,000.00 | 2020 | |
| Exelixis INC. | $3,444.42 | 2023 | Cabometyx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,078.29 | 2025 | |
| Incyte Corporation | $2,818.00 | 2022 | |
| Daiichi Sankyo INC. | $1,219.54 | 2022-2025 | Vanflyta |
| Novocure Gmbh | $200.00 | 2022 | |
| Janssen Biotech, INC. | $139.98 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $123.12 | 2024 | |
| Genentech USA, INC. | $116.66 | 2021-2025 | Polivy, Tecentriq, Columvi |
| Comsort, INC | $100.00 | 2019 | |
| Janssen Scientific Affairs, LLC | $43.13 | 2025 | Tecvayli, Talvey, Darzalex |
| Shield Therapeutics INC | $15.36 | 2024 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sreeram Maddipatla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.